NDAORALTABLET
Approved
Sep 2010
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
4/8 — Partial
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEYAZ is an oral combined oral contraceptive tablet containing drospirenone, ethinyl estradiol, and levomefolate calcium approved in 2010. It is indicated for pregnancy prevention in women of childbearing age and is formulated with added folate to reduce neural tube defects. The progestin drospirenone provides contraceptive efficacy while the levomefolate calcium supplementation addresses folate deficiency, a known risk factor for birth defects.
$0.032BPart D
Peak4.1 years to LOEProduct is in peak lifecycle with modest Part D spending; brand team focus is likely on maintaining market position and defending against generic erosion as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on BEYAZ at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.